Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its novel anti‑IL‑11 monoclonal antibody 9MW3811 has received approval from the China ...
For adults and adolescents with moderate-to-severe plaque psoriasis, selective blockade of the interleukin-23 receptor with ...
Galux, an AI-driven drug discovery company, announced on the 22nd that it successfully designed antibodies for eight disease targets using its protein design platform ‘Galux Design.’ This achievement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback